The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial

Table 2 Changes of BPRS total scores of patients who fully or partly maintained the initial treatment from baseline to endpoint among the five kinds of antipsychotic drugs

Groups	N	BPRS total score at baseline	BPRS total score at endpoint	Deduction rate of BPRS total score
Aripiprazole	23	54.00 ± 10.39	29.96 ± 9.05	0.44 ± 0.13
Risperidone	23	56.04 ± 10.39	24.87 ± 7.05	0.55 ± 0.12^ab
Quetiapine	27	58.48 ± 11.16	28.74 ± 6.21	0.50 ± 0.11
Olanzapine	21	53.10 ± 11.5	26.90 ± 4.75	0.47 ± 0.15
Ziprasidone	7	58.71 ± 14.59	25.86 ± 4.91	0.54 ± 0.13
F value		0.97	1.95	2.97
P value		> 0.05	> 0.05	0.023

Deduction rate of BPRS score: (baseline BPRS total scores − post-treatment BPRS total scores)/baseline BPRS total scores. Values are represented as mean ± SD
N: number of patients
^aComparison of risperidone with aripiprazole, P < 0.01
^bComparison of risperidone with olanzapine, P < 0.05